# Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis

> **NCT01903057** · PHASE4 · WITHDRAWN · sponsor: **Emory University**

## Conditions studied

- Trachoma
- Lymphatic Filariasis

## Interventions

- **DRUG:** azithromycin
- **DRUG:** ivermectin
- **DRUG:** albendazole
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01903057
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-02
- **Primary completion:** 2014-03
- **Final completion:** 2014-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** As of November 2013, the security situation in rural Northern Mozambique is no longer suitable for this clinical trial.
- **Last updated:** 2014-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01903057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01903057, "Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01903057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*